Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Children, adolescents, and adults 3 to 64 years of age in good health as determined by medical history, physical assessment and clinical judgement of the investigator and without influenza within the past 6 months.~Exclusion Criteria:~* History of serious disease.~* History of serious reaction following administration of vaccine or hypersensitivity to vaccine components.~* Known or suspected impairment/alteration of immune function.~* Receipt or planned receipt of seasonal trivalent influenza vaccine within 1 week before or after each study vaccination.~For additional entry criteria, please refer to protocol.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- 2x7.5adj (Type: EXPERIMENTAL): Two doses of MF59 adjuvanted (adj) A/H1N1
- 7.5adj_1_8 (Type: EXPERIMENTAL): MF59 adjuvanted (adj) A/H1N1 on days 1 and 8
- 7.5adj_1_22 (Type: EXPERIMENTAL): MF59 adjuvanted (adj) A/H1N1 on study days 1 and 22
- 15_1_22 (Type: EXPERIMENTAL): A/H1N1 on study days 1 and 22
- 2x15_1_22 (Type: EXPERIMENTAL): Two doses of A/H1N1 (one in each arm) on study days 1 and 22

Based on this trial design, predict the completion outcome and termination type (if applicable).